Clinical Trial Update: Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia [Phase 4]

View source ↗

Summary

Phase 4 study evaluating valbenazine for tardive dyskinesia in participants with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder
• Schizoaffective Disorder
• Schizophrenia
• Tardive Dyskinesia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2026-01-16